Russell Schilder, MD

Contact Dr. Schilder

925 Chestnut Street
Suite 320A
Philadelphia, PA 19107

(215) 955-8874

Medical School
University of Miami School of Medicine - 1983

Residency
Temple University Hospital

Fellowship
Temple University Hospital

Board Certification
Medical Oncology
Hematology
Internal Medicine

Hospital Appointment
Thomas Jefferson University Hospital
Methodist Hospital Division of Thomas Jefferson University Hospital

Hospital Appointment
Active Medical Staff

University Appointment

Research and Clinical Interests
Medical Oncology

Publications

Most recent Peer-reviewed Publications

1. A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: A Gynecologic Oncology Group study
2. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: A Gynecologic Oncology Group study
3. Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion
4. A phase i trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study
5. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer
6. Ovarian cancer, version 3.2012: Featured updates to the NCCN guidelines
7. Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study
8. Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
9. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study
10. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: A Gynecologic Oncology Group study
11. A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer
12. Epithelial ovarian cancer
13. A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial.
14. Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: A study of the princess margaret hospital phase II consortium
15. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study
16. mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary
17. A Phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix
18. Management of Recurrent Ovarian Carcinoma: Current Status and Future Directions
19. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash
20. A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies

View All Publications